|
Objective To slow - fast AF suppression pacemaker implantation syndrome (atrial fibrillation suppress pacing, AFSP) clinical data and programmable pacemaker follow-up data were retrospectively analyzed to explore the AFSP for atrial fibrillation (atrial fibrillation, AF) inhibition. Methods pacemaker implanted AFSP slow - fast syndrome in 21 patients, male = 7, female = 14, age = 69.71 8.49 years, a total of 28 sets of pacemaker implantation AFSP / times, were confirmed by clinical follow-up and regular 12-lead Holter (12-HOLTER) follow-up testing and AFSP program-controlled follow-up period = 5.48 ± 2.52 years, the analysis of clinical follow-up data ,12-HOLTER and AFSP programmable pacemaker follow-up data, evaluation AFSP pacing mode inhibition of long-term efficacy of atrial fibrillation. Results (a) shows AFSP clinical follow-up after pacemaker implantation, all patients were also taking β-blockers and other drugs, clinical symptoms improved significantly, which symptoms disappeared eight cases (38.1%), symptoms 13 cases (61.9 %); 5 patients developed permanent atrial fibrillation (23.81%), of which 1 patient died (4.76%); (2) 12-HOLTER follow-up testing shows atrial premature reduction (2,235.19 ± 957.51 times / 24h, 1,086.33 ± 579.41 times / 24h, P lt; 0.05); paroxysmal AF (paroxysmal atrial fibrillatio, PAF) significantly reduced heart rate (26,463.81 ± 37,742.68 times / 24h, 11,652.19 ± 23,700.75 times / 24h, P lt; 0.05); PAF continued Time (PAFT) and PAFT accounting for monitoring the percentage of time (PAFT%) and other indicators of AF burden significantly lower (6.96 ± 9.85h, 3.23 ± 6.81h, P lt; 0.05; 30.43 ± 9.40%, 11.43 ± 4.71%, P lt; 0.05); (3) cardiac ultrasound follow-up testing shows AFSP pacemaker implantation, the patient's left atrial diameter and left ventricular internal diameter no significant expansion of (39.57 ± 4.26mm, 39.29 ± 0.70mm, P gt; 0.05; 47.24 ± 4.76 mm, 48.10 ± 1.14mm, P gt; 0.05), left ventricular ejection fraction (left ventricle ejection fraction, LVEF) increased (63.85 ± 2.55%, 65.10 ± 2.48%, P lt; 0.05); (4) AFSP pacing programmable detection device shows up: atrial pacing ratio was significantly increased (56.28 ± 7.12%, 73.00 ± 7.03%, P lt; 0.01), automatic mode switching (Automatic Mode Switch, AMS) had significantly fewer (3,413.52 ± 1,802.06,2,277.10 ± 1,441.27 , P lt; 0.05). Conclusions (1) AFSP pacing and B-blockers and other drugs can be effective in treating slow - fast syndrome; (2) AFSP pacing and B-blockers and other drugs can effectively suppress atrial fibrillation, reduce the AF burden. (3) 12-HOLTER with AFSP pacemaker regular follow-up tests are available for AFSP Pacing and B-blockers and other drugs efficacy evaluation.
|